Mithradote
Home
People
  • Management
  • Strategic Advisors
Pipeline
News
Media
Contact
Mithradote
Home
People
  • Management
  • Strategic Advisors
Pipeline
News
Media
Contact
More
  • Home
  • People
    • Management
    • Strategic Advisors
  • Pipeline
  • News
  • Media
  • Contact
  • Home
  • People
    • Management
    • Strategic Advisors
  • Pipeline
  • News
  • Media
  • Contact

The first self-administered antidote against drink spiking drugs

The first self-administered antidote against drink spiking drugsThe first self-administered antidote against drink spiking drugsThe first self-administered antidote against drink spiking drugs

Mithradote Bio is a biotechnology company developing a novel medication to help prevent drug-facilitated sexual assault

Contact us to learn more

The first self-administered antidote against drink spiking drugs

The first self-administered antidote against drink spiking drugsThe first self-administered antidote against drink spiking drugsThe first self-administered antidote against drink spiking drugs

Mithradote Bio is a biotechnology company developing a novel medication to help prevent drug-facilitated sexual assault

Contact us to learn more

M-101

Our lead product, M-101, is a novel sublingual pan-antidote against benzodiazepines (i.e. Rohypnol/"roofies," Valium, Versed, etc.), "Z drugs," and other GABA agonists.


Our innovative and convenient sublingual medication allows for rapid absorption, ensuring fast action after administration, and can be easily carried at all times in case the need arises.

Mithradote Bio is developing a novel self-administered antidote to reverse the effects of drink spiking drugs

Nasdaq Spotlight interview with Sophia Lee, CEO

News

  • Home
  • Pipeline
  • News
  • Media
  • Contact

It's Not Too Late.

Copyright © 2024 Mithradote Bio, Inc. - All Rights Reserved.